Verastem's VS-7375 shows early promise in pancreatic cancer trial
Verastem Oncology reported encouraging early trial results for its KRAS G12D inhibitor VS-7375, with analysts noting the drug appears competitive in treating pancreatic cancer patients with the G12D mutation. The company's shares rose 18% following the data release from a study of over 200 patients with advanced solid tumors.
4 sourcesBig Tech stock performance
00